RDY stock news · Dr. Reddy's Laboratories
Get alerts for RDY
Follow Dr. Reddy's Laboratories (RDY) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for RDYAurinia Pharmaceuticals is suing several generic drug makers, including Dr. Reddy's Laboratories, for patent infringement.
Bad for RDYDr. Reddy's is named in active patent-infringement proceedings brought by Aurinia.
Tonix Pharmaceuticals is suing Dr. Reddy's Laboratories for copying its drug TONMYA.
Bad for RDYDr. Reddy's generic application now faces a possible delay of up to 30 months as Tonix's patent case proceeds.
Dr Reddy's Laboratories shared the details of its earnings call for the second quarter of 2027.
NeutralDr Reddy's sales fell 1.5% year over year as lenalidomide sales dropped, but its underlying base business grew by double digits. The quarter gives a mixed picture.
Dr. Reddy's got the green light from CDSCO to use Zytorvi for treating esophageal cancer.
Good for RDYDr. Reddy's won Indian approval for Zytorvi to treat esophageal cancer, adding an oncology use that could widen its reach.
12 health care stocks are changing a lot before the market opens on Tuesday.
NeutralDr Reddy's Laboratories shares fell 8.26% in Tuesday's premarket session. The article gives no company news to explain the fall, so it does not change the company's outlook.
Dr Reddy's Laboratories shared details from its earnings call for the first quarter of 2027.
NeutralDr Reddy's had lower sales and margins this quarter, while core business grew; I read this as neutral for the company's outlook.